BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000. [PMID: 2688507 DOI: 10.7326/0003-4819-111-12-992] [Cited by in Crossref: 539] [Cited by in F6Publishing: 403] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Stivelman JC. Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). Semin Dial 2017;30:142-8. [PMID: 28083917 DOI: 10.1111/sdi.12569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Langston CE, Reine NJ, Kittrell D. The use of erythropoietin. Veterinary Clinics of North America: Small Animal Practice 2003;33:1245-60. [DOI: 10.1016/s0195-5616(03)00101-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Chavers B, Schnaper HW. Risk Factors for Cardiovascular Disease in Children on Maintenance Dialysis. Advances in Renal Replacement Therapy 2001;8:180-90. [DOI: 10.1053/jarr.2001.26355] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
4 Evans RW. Quality of life assessment and the treatment of end-stage renal disease. Transplantation Reviews 1990;4:28-51. [DOI: 10.1016/s0955-470x(11)80003-0] [Cited by in Crossref: 27] [Article Influence: 0.8] [Reference Citation Analysis]
5 Ziccardi VB, Saini J, Demas PN, Braun TW. Management of the oral and maxillofacial surgery patient with end-stage renal disease. Journal of Oral and Maxillofacial Surgery 1992;50:1207-12. [DOI: 10.1016/0278-2391(92)90155-s] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
6 Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia. Annals of Oncology 1999;10:S91-4. [DOI: 10.1093/annonc/10.suppl_5.s91] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Holldack J, Burdach S, Eisberg A, Frisch J, Schulz G. Biology and pharmacology of hematopoietic growth factors. Med Pediatr Oncol 1992;20:2-9. [DOI: 10.1002/mpo.2950200703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
8 Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25:1630-1646. [PMID: 24700870 DOI: 10.1681/asn.2013060601] [Cited by in Crossref: 85] [Cited by in F6Publishing: 31] [Article Influence: 10.6] [Reference Citation Analysis]
9 Pesce M, Felaco P, Franceschelli S, Speranza L, Grilli A, De Lutiis MA, Ferrone A, Sirolli V, Bonomini M, Felaco M, Patruno A. Effect of erythropoietin on primed leucocyte expression profile. Open Biol 2014;4:140026. [PMID: 24920275 DOI: 10.1098/rsob.140026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Yessayan L, Yee J, Zasuwa G, Frinak S, Besarab A. Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study. BMC Nephrol 2014;15:119. [PMID: 25038614 DOI: 10.1186/1471-2369-15-119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney International 1999;56:253-60. [DOI: 10.1046/j.1523-1755.1999.00531.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
12 Chen L, Ling YS, Lin CH, He JX, Guan TJ. High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis. Front Public Health 2015;3:258. [PMID: 26636058 DOI: 10.3389/fpubh.2015.00258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
13 Musio F. Kidney Disease and Anemia in Elderly Patients. Clin Geriatr Med 2019;35:327-37. [PMID: 31230734 DOI: 10.1016/j.cger.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F. Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin J Am Soc Nephrol 2013;8:538-45. [PMID: 23243269 DOI: 10.2215/CJN.03440412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84 Suppl 1:3-10. [PMID: 11308268 DOI: 10.1054/bjoc.2001.1746] [Cited by in Crossref: 346] [Cited by in F6Publishing: 286] [Article Influence: 16.5] [Reference Citation Analysis]
16 Niskanen E. Hematopoietic growth factors in clinical hematology. Ann Med 1991;23:615-24. [PMID: 1777217 DOI: 10.3109/07853899109148093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Powe NR, Eggers PW, Johnson CB. Early Adoption of Cyclosporine and Recombinant Human Erythropoietin: Clinical, Economic, and Policy Issues With Emergence of High-Cost Drugs. American Journal of Kidney Diseases 1994;24:33-41. [DOI: 10.1016/s0272-6386(12)80157-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Thamer M, Richard C, Ray NF, Greer JW, Cotter DJ, Pearson BC. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. American Journal of Kidney Diseases 1996;28:235-49. [DOI: 10.1016/s0272-6386(96)90307-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Martin GR, Ongkingo JR, Turner ME, Skurow ES, Ruley EJ. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. Pediatr Nephrol 1993;7:276-80. [DOI: 10.1007/bf00853220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Goodnough LT, Shander A. Update on erythropoiesis-stimulating agents. Best Practice & Research Clinical Anaesthesiology 2013;27:121-9. [DOI: 10.1016/j.bpa.2012.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Nicola NA, Hilton DJ. General classes and functions of four-helix bundle cytokines. Adv Protein Chem 1998;52:1-65. [PMID: 9917917 DOI: 10.1016/s0065-3233(08)60432-5] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
22 Wali A, Suresh MS, Gregg AR. Antepartum Hemorrhage. In: Datta S, Hepner DL, editors. Anesthetic and Obstetric Management of High-Risk Pregnancy. New York: Springer-Verlag; 2004. pp. 87-109. [DOI: 10.1007/0-387-21572-7_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 London G, Marchais S, Guerin AP. Blood Pressure Control in Chronic Hemodialysis Patients. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, editors. Replacement of Renal Function by Dialysis. Dordrecht: Springer Netherlands; 1996. pp. 966-89. [DOI: 10.1007/978-0-585-36947-1_38] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
24 Balaskas EV, Melamed IR, Gupta A, Bargman J, Oreopoulos DG. Influence of Erythropoietin on Blood Pressure in Continuous Ambulatory Peritoneal Dialysis Patients. Perit Dial Int 1993;13:553-7. [DOI: 10.1177/089686089301302s135] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Jabs K, Warady BA. The Impact of the Dialysis Outcomes Quality Initiative Guidelines on the Care of the Pediatric End-Stage Renal Disease Patient. Advances in Renal Replacement Therapy 1999;6:97-106. [DOI: 10.1016/s1073-4449(99)70016-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997;30:532-41. [PMID: 9328369 DOI: 10.1016/s0272-6386(97)90313-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
27 Walker R, Pussell BA; Australian Renal Anaemia Group. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha. Nephrology (Carlton) 2009;14:689-95. [PMID: 19796029 DOI: 10.1111/j.1440-1797.2009.01166.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Martino MA, Vogel KM, O’brien SP, Kerstein MD. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. Journal of the American College of Surgeons 1998;187:616-9. [DOI: 10.1016/s1072-7515(98)00258-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4:470-480. [PMID: 19218474 DOI: 10.2215/cjn.05040908] [Cited by in Crossref: 121] [Cited by in F6Publishing: 46] [Article Influence: 9.3] [Reference Citation Analysis]
30 Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ; European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-7. [PMID: 11473657 DOI: 10.1046/j.1523-1755.2001.060002741.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 90] [Article Influence: 6.4] [Reference Citation Analysis]
31 Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006;11:341-6. [PMID: 16889575 DOI: 10.1111/j.1440-1797.2006.00594.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
32 Loo M, Beguin Y. The Effect of Recombinant Human Erythropoietin on Platelet Counts Is Strongly Modulated by the Adequacy of Iron Supply. Blood 1999;93:3286-93. [DOI: 10.1182/blood.v93.10.3286.410k29_3286_3293] [Cited by in Crossref: 49] [Article Influence: 2.1] [Reference Citation Analysis]
33 Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757-67. [PMID: 14871396 DOI: 10.1111/j.1523-1755.2004.00450.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
34 Silverberg DS, Wexler D, Iaina A, Schwartz D. ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE: ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE. Journal of Renal Care 2010;36:86-96. [DOI: 10.1111/j.1755-6686.2010.00164.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
35 Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993;43:1010-1014. [PMID: 8510379 DOI: 10.1038/ki.1993.142] [Cited by in Crossref: 152] [Cited by in F6Publishing: 131] [Article Influence: 5.2] [Reference Citation Analysis]
36 Topuzović N. Worsening of left ventricular diastolic function during long-term correction of anemia with erythropoietin in chronic hemodialysis patients--an assessment by radionuclide ventriculography at rest and exercise. Int J Card Imaging 1999;15:233-9. [PMID: 10472525 DOI: 10.1023/a:1006171626861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clin J Am Soc Nephrol. 2016;11:982-991. [PMID: 27094610 DOI: 10.2215/cjn.06890615] [Cited by in Crossref: 163] [Cited by in F6Publishing: 81] [Article Influence: 27.2] [Reference Citation Analysis]
38 Homoncik M, Jilma-stohlawetz P, Schmid M, Ferlitsch A, Peck-radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study: ERYTHROPOIETIN AND PLATELETS IN CIRRHOSIS. Alimentary Pharmacology & Therapeutics 2004;20:437-43. [DOI: 10.1111/j.1365-2036.2004.02088.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
39 Scott J, Phillips GC. Erythropoietin in Sports: A New Look at An Old Problem. Current Sports Medicine Reports 2005;4:224-6. [DOI: 10.1097/01.csmr.0000306212.10304.78] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
40 Schmieder RE, Langenfeld MR, Hilgers KF. Endogenous erythropoietin correlates with blood pressure in essential hypertension. Am J Kidney Dis 1997;29:376-82. [PMID: 9041213 DOI: 10.1016/s0272-6386(97)90198-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62:2167-2175. [PMID: 12427142 DOI: 10.1046/j.1523-1755.2002.00657.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 86] [Article Influence: 6.7] [Reference Citation Analysis]
42 Tedla FM, Friedman EA. The Trend Toward Geriatric Nephrology. Primary Care: Clinics in Office Practice 2008;35:515-30. [DOI: 10.1016/j.pop.2008.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
43 Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995;48:806-13. [PMID: 7474668 DOI: 10.1038/ki.1995.354] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 2.2] [Reference Citation Analysis]
44 Bazeley J, Wish JB. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. Adv Chronic Kidney Dis 2019;26:229-36. [PMID: 31477253 DOI: 10.1053/j.ackd.2019.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Geary DF, Keating LE, Vigneux A, Stephens D, Hébert D, Harvey EA. Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 2005;68:1759-65. [PMID: 16164652 DOI: 10.1111/j.1523-1755.2005.00592.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
46 Picaud J, Putet G, Salle B, Claris O. Supplémentation en fer chez les enfants prématurés traités par érythropoïétine. Archives de Pédiatrie 1999;6:657-64. [DOI: 10.1016/s0929-693x(99)80299-1] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
47 Bradley RR, Cunniff PJ, Pereira BJ, Jaber BL. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient. Am J Kidney Dis. 1999;34:349-354. [PMID: 10430986 DOI: 10.1016/s0272-6386(99)70367-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
48 Hara K, Mizutani Y, Kodera H, Miyake M, Yasuda Y, Ohara S. Successful creation of an anemia management algorithm for hemodialysis patients. Int J Nephrol Renovasc Dis 2015;8:65-75. [PMID: 26150734 DOI: 10.2147/IJNRD.S80723] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
49 Alexander SR, Balfe JW, Harvey E. Peritoneal dialysis in children. In: Gokal R, Nolph KD, editors. The Textbook of Peritoneal Dialysis. Dordrecht: Springer Netherlands; 1994. pp. 591-637. [DOI: 10.1007/978-94-011-0814-0_20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
50 Fluck R. Erythropoiesis-stimulating agents in kidney and cardiac disease. British Journal of Hospital Medicine 2006;67:533-7. [DOI: 10.12968/hmed.2006.67.10.22060] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72:e53-e90. [PMID: 30354828 DOI: 10.1161/hyp.0000000000000084] [Cited by in Crossref: 238] [Cited by in F6Publishing: 93] [Article Influence: 79.3] [Reference Citation Analysis]
52 Johansen K. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era. Int J Artif Organs 2001;24:183-5. [DOI: 10.1177/039139880102400402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Moradi Z, Maali A, Shad JS, Farasat A, Kouchaki R, Moghadami M, Ahmadi MH, Azad M. Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. Indian J Hematol Blood Transfus 2020;36:26-36. [PMID: 32174689 DOI: 10.1007/s12288-019-01170-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Ingelfinger JR. Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions. CJASN 2007;2:415-7. [DOI: 10.2215/cjn.01340307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Rowe JM, Rapoport AP. Hemopoietic Growth Factors: A Review. The Journal of Clinical Pharmacology 1992;32:486-501. [DOI: 10.1177/009127009203200602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
56 Frank H, Heusser K, Höffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney International 2004;66:832-40. [DOI: 10.1111/j.1523-1755.2004.00810.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
57 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
58 Winkelmayer WC. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin Dial 2010;23:486-91. [PMID: 21069924 DOI: 10.1111/j.1525-139x.2010.00768.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
59 Brown WS, Marsh JT, Wolcott D, Takushi R, Carr CR, Higa J, Nissenson AR. Cognitive function, mood and P3 latency: Effects of the amelioration of anemia in dialysis patients. Neuropsychologia 1991;29:35-45. [DOI: 10.1016/0028-3932(91)90092-m] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Winkelmayer WC. What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation 2011;124:2805-8. [PMID: 22184042 DOI: 10.1161/CIRCULATIONAHA.111.071985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
61 Mcnamee P, van Doorslaer E, Segaar R. Benefits and Costs of Recombinant Human Erythropoietin for End-Stage Renal Failure: A Review: Benefits and Costs of Erythropoietin. Int J Technol Assess Health Care 1993;9:490-504. [DOI: 10.1017/s0266462300005419] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Kadota K, Kamata K, Kobayashi Y, Kagaya H, Shimada S, Yoshimoto-furuie K, Echizen H. Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients. J Clin Pharm Ther 2002;27:111-9. [DOI: 10.1046/j.1365-2710.2002.00391.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Cheigh JS. How Well Is Hypertension Controlled in Hemodialysis Patients? Seminars in Dialysis 1992;5:99-102. [DOI: 10.1111/j.1525-139x.1992.tb00120.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Spivak JL. Erythropoietin use and abuse. In: Roach RC, Wagner PD, Hackett PH, editors. Hypoxia. Boston: Springer US; 2001. pp. 207-24. [DOI: 10.1007/978-1-4757-3401-0_14] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
65 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
66 Venkatesan J, Henrich WL. Cardiac Disease in Chronic Uremia: Management. Advances in Renal Replacement Therapy 1997;4:249-66. [DOI: 10.1016/s1073-4449(97)70033-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011;26:3980-6. [PMID: 21505096 DOI: 10.1093/ndt/gfr160] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
68 Weigert AL, Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci. 1998;316:94-104. [PMID: 9704663 DOI: 10.1097/00000441-199808000-00005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 2.8] [Reference Citation Analysis]
69 Yousaf F, Spinowitz B. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin? Curr Hypertens Rep 2016;18. [DOI: 10.1007/s11906-016-0629-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
70 Katz SD. Mechanisms and Treatment of Anemia in Chronic Heart Failure. Congest Heart Failure 2004;10:243-7. [DOI: 10.1111/j.1527-5299.2004.03298.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
71 Mccullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease. Am J Nephrol 2013;37:549-58. [DOI: 10.1159/000351175] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
72 Rosati A, Ravaglia F, Panichi V. Improving Erythropoiesis Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: The Role of Hepcidin and Hemodiafiltration Online. Blood Purif 2018;45:139-46. [PMID: 30959500 DOI: 10.1159/000485314] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
73 Zappacosta AR, Perras ST, Bell A. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. The American Journal of Medicine 1991;91:229-32. [DOI: 10.1016/0002-9343(91)90120-m] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
74 Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008;25:1215-28. [PMID: 18931828 DOI: 10.1007/s12325-008-0111-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
75 Chan PC, Liu P, Cronin C, Heathcote J, Uldall R. The Use of Nuclear Magnetic Resonance Imaging in Monitoring Total Body Iron in Hemodialysis Patients With Hemosiderosis Treated With Erythropoietin and Phlebotomy. American Journal of Kidney Diseases 1992;19:484-9. [DOI: 10.1016/s0272-6386(12)80959-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
76 Glaspy J. Anemia and fatigue in cancer patients. Cancer 2001;92:1719-24. [DOI: 10.1002/1097-0142(20010915)92:6+<1719::aid-cncr1503>3.0.co;2-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
77 Goodkin DA. Use of erythropoietic stimulating agents in the setting of renal disease. In: Elliott SG, Foote MA, Molineux G, editors. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Basel: Birkhäuser; 2009. pp. 225-48. [DOI: 10.1007/978-3-7643-8698-6_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Powe NR, Griffiths RI, Anderson GF, de Lissovoy G, Watson AJ, Greer JW, Herbert RJ, Whelton PK. Medicare Payment Policy and Recombinant Erythropoietin Prescribing for Dialysis Patients. American Journal of Kidney Diseases 1993;22:557-67. [DOI: 10.1016/s0272-6386(12)80929-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Zauli G, Catani L. Human megakaryocyte biology and pathophysiology. Critical Reviews in Oncology/Hematology 1995;21:135-57. [DOI: 10.1016/1040-8428(94)00171-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
80 Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. American Heart Journal 2000;139:1000-8. [DOI: 10.1067/mhj.2000.105300] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
81 Szycher M. End-stage renal disease (ESRD) and vascular access grafting: a critical review. J Biomater Appl 1999;13:297-350. [PMID: 10340212 DOI: 10.1177/088532829901300403] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
82 Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. American Journal of Health-System Pharmacy 2008;65:1711-9. [DOI: 10.2146/ajhp070526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
83 Grandaliano G, Teutonico A, Allegretti A, Losappio R, Mancini A, Gesualdo L, Schena FP, Pertosa G. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int 2003;64:715-9. [PMID: 12846770 DOI: 10.1046/j.1523-1755.2003.00120.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
84 Lim P, Wei Y, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrology Dialysis Transplantation 1999;14:2680-7. [DOI: 10.1093/ndt/14.11.2680] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 4.7] [Reference Citation Analysis]
85 Schulman G. The dose of dialysis in hemodialysis patients: impact on nutrition. Semin Dial 2004;17:479-88. [PMID: 15660579 DOI: 10.1111/j.0894-0959.2004.17609.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
86 Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematology 2003;31:290-9. [DOI: 10.1016/s0301-472x(03)00006-7] [Cited by in Crossref: 313] [Cited by in F6Publishing: 66] [Article Influence: 16.5] [Reference Citation Analysis]
87 Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney International 2002;61:S44-8. [DOI: 10.1046/j.1523-1755.61.s80.9.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
88 Spivak JL. The blood in systemic disorders. Lancet. 2000;355:1707-1712. [PMID: 10905258 DOI: 10.1016/s0140-6736(00)02249-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
89 Casserly LF, Dember LM. Thrombosis in End‐Stage Renal Disease. Seminars in Dialysis 2003;16:245-56. [DOI: 10.1046/j.1525-139x.2003.16048.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
90 Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1993;94:401-6. [PMID: 8475933 DOI: 10.1016/0002-9343(93)90151-e] [Cited by in Crossref: 33] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
91 Vainchenker W, Debili N, Mouthon MA, Wendling F. Megakaryocytopoiesis: cellular aspects and regulation. Crit Rev Oncol Hematol 1995;20:165-92. [PMID: 7576196 DOI: 10.1016/1040-8428(94)00159-q] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
92 Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536-50. [PMID: 23802504 DOI: 10.1111/bcp.12195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
93 Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol 2020;33:267-75. [PMID: 31782127 DOI: 10.1007/s40620-019-00680-5] [Reference Citation Analysis]
94 Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997;29:319-33. [PMID: 9041207 DOI: 10.1016/s0272-6386(97)90192-x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
95 Higashijima Y, Tanaka T, Nangaku M. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Expert Opinion on Drug Discovery 2013;8:965-76. [DOI: 10.1517/17460441.2013.796358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
96 Sparling EA, Nelson CL, Lavender R, Smith J. The use of erythropoietin in the management of Jehovah's Witnesses who have revision total hip arthroplasty. J Bone Joint Surg Am 1996;78:1548-52. [PMID: 8876583 DOI: 10.2106/00004623-199610000-00013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
97 Spentzos D, Sytkowski AJ. Clinical Applications of Recombinant Human Erythropoietin. In: Dembowsky K, Stadler P, editors. Novel Therapeutic Proteins. Wiley; 2000. pp. 29-57. [DOI: 10.1002/9783527613021.ch02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Fjornes T. Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia. J Oncol Pharm Pract 1999;5:22-31. [DOI: 10.1177/107815529900500102] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 Hafizi R, Imeri F, Wenger RH, Huwiler A. S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P1 and S1P3 Receptor Activation and HIF-2α Stabilization. Int J Mol Sci 2021;22:9467. [PMID: 34502385 DOI: 10.3390/ijms22179467] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Pae WE, Anderson JM, Blackstone EH, Boroevetz HS, Ciarkowski A, Copeland JG, Costanzo-nordin MR, Daase K, Dew MA, Domanski MJ, Eidleman BH, Evans RW, Farrar DJ, Frazier O, Griffith BP, Hahn C, Hill J, Hunt S, Kendell K, Kormos RL, Levin HR, Mancini DM, Mccarthy PM, Mcnamara D, O’rourke FK, Parker L, Pennington D, Poirier VL, Portner PM, Rose EA, Sapirstein W, Schron E, Shanker R, Subramanian R, Wallwork J, Stevenson LW, Pennington D, Copeland JG, Frazier O, Griffith BP, Hahn C, Hill J, Kaiser LR, Magovern GJ, Pae WE, Rose EA. Bethesda conference: conference for the design of clinical trials to study circulatory support devices for chronic heart failure. The Annals of Thoracic Surgery 1998;66:1452-65. [DOI: 10.1016/s0003-4975(97)01375-1] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
101 Whittington R, Barradell LB, Benfield P. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. Pharmacoeconomics 1993;3:45-82. [PMID: 10146987 DOI: 10.2165/00019053-199303010-00006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
102 Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-82. [PMID: 17942772 DOI: 10.2215/CJN.02380607] [Cited by in Crossref: 91] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
103 Ongkingco JRC, Ruley EJ, Turner ME. Use of Low-Dose Subcutaneous Recombinant Human Erythropoietin in End-Stage Renal Disease: Experience With Children Receiving Continuous Cycling Peritoneal Dialysis. American Journal of Kidney Diseases 1991;18:446-50. [DOI: 10.1016/s0272-6386(12)80112-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Yorgin PD, Al-uzri A. Management of renal anemia. In: Warady BA, Schaefer FS, Fine RN, Alexander SR, editors. Pediatric Dialysis. Dordrecht: Springer Netherlands; 2004. pp. 295-331. [DOI: 10.1007/978-94-007-1031-3_19] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous Stem-Cell Transplantation Can Be Performed Safely Without the Use of Blood-Product Support. JCO 2004;22:4087-94. [DOI: 10.1200/jco.2004.01.144] [Cited by in Crossref: 38] [Cited by in F6Publishing: 2] [Article Influence: 2.1] [Reference Citation Analysis]
106 Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR. Low-Dose Recombinant Human Erythropoietin Therapy in Chronic Hemodialysis Patients. American Journal of Kidney Diseases 1991;18:60-4. [DOI: 10.1016/s0272-6386(12)80291-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
107 Wolff M, Jelkmann W. Erythropoiesis and erythropoietin levels in renal transplant recipients. Klin Wochenschr 1991;69:53-8. [DOI: 10.1007/bf01666817] [Cited by in Crossref: 19] [Article Influence: 0.6] [Reference Citation Analysis]
108 Katz SD, Mancini D, Androne AS, Hryniewicz K. Treatment of anemia in patients with chronic heart failure. Journal of Cardiac Failure 2004;10:S13-6. [DOI: 10.1016/j.cardfail.2004.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
109 Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-8. [PMID: 16129210 DOI: 10.1053/j.ajkd.2005.05.018] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
110 Agrawal V, Mukherjee S, Kosuri R, Dumler F. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience. Am J Ther 2010;17:469-75. [PMID: 19770634 DOI: 10.1097/MJT.0b013e3181b28b59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
111 Matzke GR. Pharmacotherapeutic Consequences of Recent Advances in Hemodialysis Therapy. Ann Pharmacother 1994;28:512-4. [DOI: 10.1177/106002809402800415] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
112 Herrera J, Nava M, Romero F, Rodríguez-iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. American Journal of Kidney Diseases 2001;37:750-7. [DOI: 10.1016/s0272-6386(01)80124-4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
113 Pitler LR. Hematopoietic growth factors in clinical practice. Semin Oncol Nurs 1996;12:115-29. [PMID: 8727799 DOI: 10.1016/s0749-2081(96)80006-4] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
114 Shigematsu T, Takami H, Shimizu T, Shimoyama H, Kim S, Hirose S, Sakai T, Kono T, Mochizuki T, Nishio K, Degawa H, Motomiya Y. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study. Ther Apher Dial 2008;12:469-74. [PMID: 19140845 DOI: 10.1111/j.1744-9987.2008.00637.x] [Reference Citation Analysis]
115 von Drygalski A, Biller J. Anemia in Cystic Fibrosis: Incidence, Mechanisms, and Association With Pulmonary Function and Vitamin Deficiency. Nutr Clin Pract 2008;23:557-63. [DOI: 10.1177/0884533608323426] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
116 Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14. [PMID: 17910755 DOI: 10.1186/1750-4732-1-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
117 Evans R, Van Der Cammen T, Verschoor C, Harwood R, Ebrahim S. Quality of life. The Lancet 1991;338:636-7. [DOI: 10.1016/0140-6736(91)90649-a] [Cited by in Crossref: 16] [Article Influence: 0.5] [Reference Citation Analysis]
118 Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003;14:2654-61. [PMID: 14514745 DOI: 10.1097/01.asn.0000088026.88074.20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
119 Imai Y, Sekino H, Fujikura Y, Munakata M, Minami N, Hashimoto J, Sakuma H, Watanabe N, Misawa S, Nishiyama A, Abe K. Pressor Effect of Recombinant Human Erythropoietin: Results of Ambulatory Blood Pressure Monitoring and Home Blood Pressure Measurements. Clinical and Experimental Hypertension 2009;17:485-506. [DOI: 10.3109/10641969509037420] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
120 Mccullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D, Eapen M, Hirsch B, Kuter D, Lazarus E, Pamphilon D, Stroncek D, Sugarman J, Wilson R. Hematopoietic growth factors-use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008;48:2008-25. [DOI: 10.1111/j.1537-2995.2008.01788.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
121 Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 2004;107:1-16. [PMID: 15567546 DOI: 10.1016/j.clineuro.2004.07.012] [Cited by in Crossref: 266] [Cited by in F6Publishing: 172] [Article Influence: 15.6] [Reference Citation Analysis]
122 Gillon J, Bell K, Prescott RJ. Autologous Transfusion - Too Far, Too Soon? Vox Sanguinis 1991;61:81-3. [DOI: 10.1111/j.1423-0410.1991.tb00250.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
123 Zhang J, Wu Y, Xu J, Ye W, Zhang Y, Weng H, Shi W, Xu G, Lu L, Dai W, Sinclair SH, Li W, Xu G. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sin 2008;29:1383-90. [DOI: 10.1111/j.1745-7254.2008.00885.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
124 Vullaganti S, Goldsmith J, Teruya S, Alvarez J, Helmke S, Maurer MS. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. J Geriatr Cardiol 2014;11:100-5. [PMID: 25009558 DOI: 10.3969/j.issn.1671-5411.2014.02.002] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
125 Marsh WA, Rascati KL. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clinical Therapeutics 1999;21:1443-55. [DOI: 10.1016/s0149-2918(00)80003-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
126 Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Semin Dial 2009;22:64-9. [PMID: 19175537 DOI: 10.1111/j.1525-139X.2008.00518.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney International 2003;63:1086-93. [DOI: 10.1046/j.1523-1755.2003.00826.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
128 Kim SM, Kim KM, Kwon SK, Kim HY. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. J Korean Med Sci 2016;31:55-60. [PMID: 26770038 DOI: 10.3346/jkms.2016.31.1.55] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
129 Morris AT, Ronco C. Erythropoietin Therapy in Peritoneal Dialysis Patients. Perit Dial Int 2000;20:178-82. [DOI: 10.1177/089686080002002s33] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
130 Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9. [PMID: 10073612 DOI: 10.1681/ASN.V103610] [Cited by in Crossref: 189] [Cited by in F6Publishing: 58] [Article Influence: 8.2] [Reference Citation Analysis]
131 Shimamatsu K, Inamasu H. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp 2013;74:5-8. [PMID: 24384988 DOI: 10.1016/j.curtheres.2012.12.001] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
132 Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol 2008;154:529-41. [PMID: 18362898 DOI: 10.1038/bjp.2008.89] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
133 Amgen Anaemia Advisory Group. Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002;7:S173-80. [DOI: 10.1111/j.1440-1797.2002.tb00530.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
134 Hamza E, Metzinger L, Metzinger-Le Meuth V. Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. Cells 2020;9:E2039. [PMID: 32899941 DOI: 10.3390/cells9092039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Rutsky EA, Rostand SG. The Management of Coronary Artery Disease in Patients with End-Stage Renal Disease. In: Parfrey PS, Harnett JD, editors. Cardiac Dysfunction in Chronic Uremia. Boston: Springer US; 1992. pp. 231-46. [DOI: 10.1007/978-1-4615-3902-5_15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
136 Hörl WH. [Thrombocytopathy and blood complications in uremia]. Wien Klin Wochenschr 2006;118:134-50. [PMID: 16773479 DOI: 10.1007/s00508-006-0574-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
137 Goh B, Ong L, Sivanandam S, Lim T, Morad Z; FOR THE BIOGENERIC EPO STUDY GROUP*. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology 2007;12:431-6. [DOI: 10.1111/j.1440-1797.2007.00831.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
138 Cardier JE, Erickson-Miller CL, Murphy MJ Jr. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. Stem Cells 1997;15:286-90. [PMID: 9253112 DOI: 10.1002/stem.150286] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
139 Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Antiviral therapy in HCV-infected decompensated cirrhotics. Saudi J Gastroenterol 2010;16:310-4. [PMID: 20871208 DOI: 10.4103/1319-3767.70632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
140 Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6:93-102. [PMID: 19325171 DOI: 10.3121/cmr.2008.811] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
141 McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62. [PMID: 18482185 DOI: 10.1111/j.1537-2995.2008.01749.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 8.6] [Reference Citation Analysis]
142 Edmunds ME, Walls J. Pathogenesis of Seizures During Recombinant Human Erythropoietin Therapy. Seminars in Dialysis 1991;4:163-7. [DOI: 10.1111/j.1525-139x.1991.tb00080.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
143 Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36. [PMID: 18760517 DOI: 10.1053/j.ajkd.2008.05.029] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
144 Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, Belo L, Reis F, Santos-Silva A. Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sci 2016;151:147-56. [PMID: 26924494 DOI: 10.1016/j.lfs.2016.02.088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
145 Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 [PMID: 34046470 DOI: 10.12998/wjcc.v9.i15.3680] [Reference Citation Analysis]
146 Berns JS. Reviews: Should the Target Hemoglobin for Patients with Chronic Kidney Disease Treated with Erythropoietic Replacement Therapy be Changed?: HEMOGLOBIN TARGET IN CKD. Seminars in Dialysis 2005;18:22-9. [DOI: 10.1111/j.1525-139x.2005.18105.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
147 Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS One 2017;12:e0172735. [PMID: 28249030 DOI: 10.1371/journal.pone.0172735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
148 K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1-153. [PMID: 15806502 DOI: 10.1053/j.ajkd.2005.01.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
149 Wauters I, Pat K, Vansteenkiste J. Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ther Clin Risk Manag 2006;2:175-86. [PMID: 18360591 DOI: 10.2147/tcrm.2006.2.2.175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
150 Stefanidis I, Mertens P, Wurth P, Bach R, Makropoulos W, Mann H, Heintz B. Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis. Int J Artif Organs 2001;24:367-73. [DOI: 10.1177/039139880102400608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
151 Ketley NJ, Newland AC. Haemopoietic growth factors. Postgrad Med J 1997;73:215-21. [PMID: 9156123 DOI: 10.1136/pgmj.73.858.215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
152 Hoffman R. The Role of Other Hemopoietic Growth Factors and the Marrow Microenvironment in Megakaryocytopoiesis. In: Kuter DJ, Hunt P, Sheridan W, Zucker-franklin D, editors. Thrombopoiesis and Thrombopoietins. Totowa: Humana Press; 1997. pp. 165-78. [DOI: 10.1007/978-1-4612-3958-1_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
153 Berns JS. Moving Away From Hemoglobin-Based Anemia Performance Measures in Dialysis Patients. American Journal of Kidney Diseases 2014;64:486-8. [DOI: 10.1053/j.ajkd.2014.06.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Spinowitz BS, Arslanian J, Charytan C, Golden RA, Rascoff J, Galler M. Impact of Epoetin Beta on Dialyzer Clearance and Heparin Requirements. American Journal of Kidney Diseases 1991;18:668-73. [DOI: 10.1016/s0272-6386(12)80607-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
155 Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 2011;58:591-8. [PMID: 21715072 DOI: 10.1053/j.ajkd.2011.03.031] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 6.6] [Reference Citation Analysis]
156 De Franceschi L, Olivieri O, Girelli D, Lupo A, Bernich P, Corrocher R. Red blood cell cation transports in uraemic anaemia: evidence for an increased K/Cl co-transport activity. Effects of dialysis and erythropoietin treatment. Eur J Clin Invest 1995;25:762-8. [PMID: 8557063 DOI: 10.1111/j.1365-2362.1995.tb01955.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
157 Hung PH, Yeh CC, Hsiao CY, Muo CH, Hung KY, Tsai KJ. Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan. J Am Heart Assoc 2021;10:e019529. [PMID: 34176302 DOI: 10.1161/JAHA.120.019529] [Reference Citation Analysis]
158 Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, Mccauley M, Antman K, Anderson KC. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994;87:153-61. [DOI: 10.1111/j.1365-2141.1994.tb04886.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
159 Bloom RD, Bolin P, Gandra SR, Scarlata D, Petersen J. Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study. Transplant Proc 2011;43:1593-600. [PMID: 21693239 DOI: 10.1016/j.transproceed.2011.02.009] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
160 Eberst ME, Berkowitz LR. Hemostasis in renal disease: Pathophysiology and management. The American Journal of Medicine 1994;96:168-79. [DOI: 10.1016/0002-9343(94)90138-4] [Cited by in Crossref: 94] [Cited by in F6Publishing: 64] [Article Influence: 3.4] [Reference Citation Analysis]
161 Lazarus JM, Hakim RM, Newell J. Recombinant Human Erythropoietin and Phlebotomy in the Treatment of Iron Overload in Chronic Hemodialysis Patients. American Journal of Kidney Diseases 1990;16:101-8. [DOI: 10.1016/s0272-6386(12)80562-2] [Cited by in Crossref: 16] [Article Influence: 0.5] [Reference Citation Analysis]
162 Kennelly C, Esaian D. Drug-induced cardiovascular adverse events in the intensive care unit. Crit Care Nurs Q 2013;36:323-34. [PMID: 24002423 DOI: 10.1097/CNQ.0b013e3182a10c2a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Rusthoven J. The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host. Can J Infect Dis 1991;2:74-88. [PMID: 22529714 DOI: 10.1155/1991/782768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
164 El-din MM, Attia FM, Labib SM, Omar W. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis. International Journal of Laboratory Hematology 2010;32:336-43. [DOI: 10.1111/j.1751-553x.2009.01186.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Warady BA, Jabs K. New Hormones in the Therapeutic Arsenal of Chronic Renal Failure: Growth Hormone and Erythropoietin. Pediatric Clinics of North America 1995;42:1551-77. [DOI: 10.1016/s0031-3955(16)40098-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
166 Heinze G, Kainz A, Hörl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009;339:b4018. [PMID: 19854839 DOI: 10.1136/bmj.b4018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
167 Labonia WD. l-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. American Journal of Kidney Diseases 1995;26:757-64. [DOI: 10.1016/0272-6386(95)90439-5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
168 Thompson FL, Powers JS, Graber SE, Krantz SB. Use of recombinant human erythropoietin to enhance autologous blood donation in a patient with multiple red cell allo-antibodies and the anemia of chronic disease. The American Journal of Medicine 1991;90:398-400. [DOI: 10.1016/0002-9343(91)80024-g] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
169 Staško J, Funiak S, Funiaková S, Peterková M, Ivanková J, Makovický P, Kubisz P. Some Hemostatic Changes During the Course of Hemodialysis in Patients with Erythropoietin Treatment. Clin Appl Thromb Hemost 1997;3:141-3. [DOI: 10.1177/107602969700300214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Evans RW. Psychosocial aspects of heart transplantation: a comparative analysis. In: Walter PJ, editor. Quality of Life after Open Heart Surgery. Dordrecht: Springer Netherlands; 1992. pp. 469-82. [DOI: 10.1007/978-94-011-2640-3_46] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-49. [PMID: 18345959 DOI: 10.1517/14656566.9.5.839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
172 Goodkin DA. The normal hematocrit cardiac trial revisited. Semin Dial 2009;22:495-502. [PMID: 19650856 DOI: 10.1111/j.1525-139X.2009.00620.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
173 Muirhead N. Erythropoietin Is a Cause of Access Thrombosis. Seminars in Dialysis 1993;6:184-8. [DOI: 10.1111/j.1525-139x.1993.tb00293.x] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
174 Harris DCH, Lawrence S, Chapman JR, Roger SD, Stewart JH. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Australian and New Zealand Journal of Medicine 1991;21:693-700. [DOI: 10.1111/j.1445-5994.1991.tb01372.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
175 Jabs K. The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 1996;10:324-7. [PMID: 8792397 DOI: 10.1007/BF00866771] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
176 Abdelfatah A, Motte G, Ducloux D, Chalopin J. Determinants of mean arterial pressure and pulse pressure in chronic haemodialysis patients. J Hum Hypertens 2001;15:775-9. [DOI: 10.1038/sj.jhh.1001273] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
177 Eschbach JW. Erythropoietin Is Not a Cause of Access Thrombosis. Seminars in Dialysis 1993;6:180-4. [DOI: 10.1111/j.1525-139x.1993.tb00292.x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
178 Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217-22. [PMID: 9211366 DOI: 10.1038/ki.1997.323] [Cited by in Crossref: 150] [Cited by in F6Publishing: 116] [Article Influence: 6.0] [Reference Citation Analysis]
179 Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485-491. [PMID: 18182579 DOI: 10.1182/blood-2007-03-079681] [Cited by in Crossref: 356] [Cited by in F6Publishing: 321] [Article Influence: 25.4] [Reference Citation Analysis]
180 Zabaneh R, Roger SD, El-Shahawy M, Roppolo M, Runyan G, O'Neil J, Qiu P. Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. Perit Dial Int 2015;35:481-9. [PMID: 24584613 DOI: 10.3747/pdi.2012.00224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
181 Whitsett CF. The Role of Hematopoietic Growth Factors in Transfusion Medicine. Hematology/Oncology Clinics of North America 1995;9:23-68. [DOI: 10.1016/s0889-8588(18)30109-6] [Cited by in Crossref: 12] [Article Influence: 0.4] [Reference Citation Analysis]
182 Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA. The effect of epoetin dose on hematocrit. Kidney Int 2008;73:347-53. [PMID: 18004296 DOI: 10.1038/sj.ki.5002688] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
183 Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer. 2005;5:543-555. [PMID: 15965494 DOI: 10.1038/nrc1648] [Cited by in Crossref: 115] [Cited by in F6Publishing: 97] [Article Influence: 6.8] [Reference Citation Analysis]
184 Kang ES, Wang YB, Cardenas R, Tevlin MT, Mishra S, Acchiardo SR. Biphasic changes in nitric oxide generation in hemodialyzed patients with end-stage renal disease treated with recombinant human erythropoietin. Am J Med Sci 2000;319:149-57. [PMID: 10746825 DOI: 10.1097/00000441-200003000-00004] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
185 Muirhead N, Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, Gitlin M, Mayne TJ. Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2011;15:87-94. [PMID: 21138518 DOI: 10.1111/j.1542-4758.2010.00508.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
186 Böhlke M, Giesteira R, Castilho C, Pinheiro B, Irigoyen MC, Poli de Figueiredo CE. Acetylsalicylic acid mitigates erythropoietin-associated blood pressure increase in nonuremic rats. Clin Exp Hypertens 2015;37:235-40. [PMID: 25314608 DOI: 10.3109/10641963.2014.943403] [Reference Citation Analysis]
187 Kei T, Mistry N, Curley G, Pavenski K, Shehata N, Tanzini RM, Gauthier M, Thorpe K, Schweizer TA, Ward S, Mazer CD, Hare GMT. Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis. Can J Anesth/J Can Anesth 2019;66:716-31. [DOI: 10.1007/s12630-019-01351-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
188 Tang Y, Katz SD. Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options. Circulation 2006;113:2454-61. [DOI: 10.1161/circulationaha.105.583666] [Cited by in Crossref: 263] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]
189 Boyle SM, Berns JS. Erythropoietin and Resistant Hypertension in CKD. Seminars in Nephrology 2014;34:540-9. [DOI: 10.1016/j.semnephrol.2014.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
190 Fried W. Erythropoietin and erythropoiesis. Exp Hematol 2009;37:1007-15. [PMID: 19500646 DOI: 10.1016/j.exphem.2009.05.010] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 5.3] [Reference Citation Analysis]
191 Van Buren PN. Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis. Curr Cardiol Rep 2016;18:125. [PMID: 27796862 DOI: 10.1007/s11886-016-0805-y] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
192 Balaskas EV, Melamed IR, Gupta A, Bargman J, Oreopoulos DG. Effect of Erythropoietin Treatment on Nutritional Status of Continuous Ambulatory Peritoneal Dialysis Patients. Perit Dial Int 1993;13:544-9. [DOI: 10.1177/089686089301302s133] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
193 Frenken LA, Struijk DG, Coppens PJ, Tiggeler RG, Krediet RT, Koene RA. Intraperitoneal Administration of Recombinant Human Erythropoietin. Perit Dial Int 1992;12:378-83. [DOI: 10.1177/089686089201200409] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
194 Khemiri H, Maresca M, Gestreau C. Carbamylated erythropoietin enhances mice ventilatory responses to changes in O2 but not CO2 levels. Respir Physiol Neurobiol 2016;232:1-12. [PMID: 27317882 DOI: 10.1016/j.resp.2016.06.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Gahl GM, Eckardt K. Erythropoietin 1997: A Brief Update. Perit Dial Int 1997;17:84-90. [DOI: 10.1177/089686089701702s17] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009;24:919-925. [PMID: 18840893 DOI: 10.1093/ndt/gfn543] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
197 Adamson JW. Erythropoietin: its role in the regulation of erythropoiesis and as a therapeutic in humans. Biotechnology 1991;19:351-63. [PMID: 1786475 DOI: 10.1016/b978-0-7506-9120-8.50019-6] [Reference Citation Analysis]
198 Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110-118. [PMID: 12087568 DOI: 10.1053/ajkd.2002.33919] [Cited by in Crossref: 150] [Cited by in F6Publishing: 98] [Article Influence: 7.5] [Reference Citation Analysis]
199 Yugavathy N, Huri HZ, Kun LS, Bin Abdul Gafor AH, Geot WM, Bavanandan S, Seng WH. Clinical and genetic markers of erythropoietin deficiency anemia in chronic kidney disease (predialysis) patients. Biomark Med 2020;14:1099-108. [PMID: 32969247 DOI: 10.2217/bmm-2020-0205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Beccari M. Seizures in Dialysis Patients Treated with Recombinant Erythropoietin. Review of the Literature and Guidelines for Prevention. Int J Artif Organs 1994;17:5-13. [DOI: 10.1177/039139889401700102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
201 Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid?? (Thalidomide) Capsules: A Review of the First 18 Months of Spontaneous Postmarketing Adverse Event Surveillance, Including Off-Label Prescribing. Drug Safety 2001;24:87-117. [DOI: 10.2165/00002018-200124020-00002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
202 Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 2007;49:135-42. [PMID: 17185154 DOI: 10.1053/j.ajkd.2006.09.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
203 Ebbers HC, Mantel-teeuwisse AK, Moors EH, Schellekens H, Leufkens HG. Todayʼs Challenges in Pharmacovigilance: What can we Learn from Epoetins? Drug Safety 2011;34:273-87. [DOI: 10.2165/11586350-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
204 Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 2004;65:266-73. [PMID: 14675059 DOI: 10.1111/j.1523-1755.2004.00357.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
205 Tàssies D, Reverter JC, Cases A, Calls J, Escolar G, Ordinas A. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function. Am J Hematol 1998;59:105-9. [DOI: 10.1002/(sici)1096-8652(199810)59:2<105::aid-ajh1>3.0.co;2-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
206 Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-9. [DOI: 10.1182/blood.v95.9.2983.009k27_2983_2989] [Cited by in Crossref: 195] [Article Influence: 8.9] [Reference Citation Analysis]
207 Kornowski R, Schwartz D, Joffe A, Pines A, Aderka D, Levo Y. Erythropoietin Therapy Obviates the Need for Recurrent Transfusions in a Patient with Severe Hemolysis due to Prosthetic Valves. Chest 1992;102:315-6. [DOI: 10.1378/chest.102.1.315] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
208 Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in Patients With Chronic Renal Failure—An Interim Report. American Journal of Kidney Diseases 1993;22:3-12. [DOI: 10.1016/0272-6386(93)70176-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
209 Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf 2009;18:932-40. [PMID: 19572312 DOI: 10.1002/pds.1799] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
210 Gejyo F, Saito A, Akizawa T, Takashi Akiba, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M. 2004 Japanese Society for Dialysis Therapy Guidelines for Renal Anemia in Chronic Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2004;8:443-59. [DOI: 10.1111/j.1774-9987.2004.00199.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
211 Locatelli F, Pedrazzoli P, Barosi G, Zecca M, Porta F, Liberato L, Gambarana D, Nespoli L, Cazzola M. Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. Br J Haematol 1992;80:545-9. [PMID: 1581240 DOI: 10.1111/j.1365-2141.1992.tb04571.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
212 Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001;38:33-9. [PMID: 11523026 DOI: 10.1016/s0037-1963(01)90128-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
213 Muirhead N. Erythropoietin and renal transplantation. Kidney International 1999;55:S86-92. [DOI: 10.1046/j.1523-1755.1999.055suppl.69086.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
214 Nissenson AR. Erythropoietin and Peritoneal Dialysis: The Efficacy of Intraperitoneal Dosing. Perit Dial Int 1992;12:350-2. [DOI: 10.1177/089686089201200403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
215 van Kamp H, Prinsze-Postema TC, Kluin PM, den Ottolander GJ, Beverstock GC, Willemze R, Fibbe WE. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 1991;78:488-93. [PMID: 1911340 DOI: 10.1111/j.1365-2141.1991.tb04477.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 1.2] [Reference Citation Analysis]
216 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
217 Abbas EE, Afioni N, Al Wakeel J, Bakr MA, Dham R, Donia A, Droubi N, Khidir E, Mathew CM, Mitwali AH, Naga S, Pingle A, Rashed A, Roshdy A, Shaheen F, Shaibani B, Shaibani FM, Shaker DS, Sheiban A, Solieman M. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis. Transplant Proc 2004;36:1805-11. [PMID: 15350482 DOI: 10.1016/j.transproceed.2004.07.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Muller P, Lozano D. Control of blood loss in the treatment of a Jehovah's Witness with massive thermal injuries using a fibroblast derived temporary skin substitute. Burns 2004;30:483-7. [PMID: 15225917 DOI: 10.1016/j.burns.2003.12.018] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
219 Weiss LG, Clyne N, Fihlho JD, Frisenette‐fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial. Nephrology Dialysis Transplantation 2000;15:2014-9. [DOI: 10.1093/ndt/15.12.2014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
220 Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opinion on Investigational Drugs 2016;25:901-16. [DOI: 10.1080/13543784.2016.1182981] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
221 Rocco MV, Flanigan MJ, Beaver S, Frederick P, Gentile DE, McClellan WM, Polder J, Prowant BF, Taylor L, Helgerson SD. Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 1997;30:165-73. [PMID: 9261026 DOI: 10.1016/s0272-6386(97)90049-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
222 Agarwal R. Individualizing Decision-Making—Resurrecting the Doctor-Patient Relationship in the Anemia Debate. CJASN 2010;5:1340-6. [DOI: 10.2215/cjn.02830310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
223 Amgen Anaemia Advisory Group. Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia*. Nephrology 2002;7:315-23. [DOI: 10.1046/j.1440-1797.2002.00133.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Neustein SM, Bronheim D, Galla J, Litwak R, Rand J, Scott BH, Hartman AR, Poppers PJ, Bert AA, Feng WC, Singh AK, Corwin HL, Gettinger A, Erslev AJ. Case 1—1993 The role of erythropoietin in Jehovah's Witnesses requiring cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 1993;7:95-102. [DOI: 10.1016/1053-0770(93)90127-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
225 Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Giordano N, Nuti R. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag. 2014;10:641-650. [PMID: 25143739 DOI: 10.2147/tcrm.s61551] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
226 Bergen D, Ristanovic R, Gorelick P, Kathpalia S. Seizures and Renal Failures. Int J Artif Organs 1994;17:247-51. [DOI: 10.1177/039139889401700501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
227 Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, Toyonaga J, Sugawara K, Takeda K. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra 2015;5:79-86. [PMID: 26648974 DOI: 10.1159/000441154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
228 Warady BA, Alexander SR, Balfe JW, Harvey E. Peritoneal dialysis in children. In: Gokal R, Khanna R, Krediet RT, Nolph KD, editors. Textbook of Peritoneal Dialysis. Dordrecht: Springer Netherlands; 2000. pp. 667-708. [DOI: 10.1007/978-94-017-3225-3_22] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
229 Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M 3rd, Wara W, Marcus KC, Vijayakumar S. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77:1996-2002. [PMID: 9667681 DOI: 10.1038/bjc.1998.331] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
230 Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 2003;18:1055-62. [PMID: 12883982 DOI: 10.1007/s00467-003-1214-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
231 Nissenson AR. Erythropoietin Treatment in Peritoneal Dialysis Patients. Perit Dial Int 1994;14:63-9. [DOI: 10.1177/089686089401403s13] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Lacson E Jr, Lazarus M. Dialysis time: does it matter? A reappraisal of existing literature. Curr Opin Nephrol Hypertens 2011;20:189-94. [PMID: 21178614 DOI: 10.1097/MNH.0b013e3283432187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
233 Reuter SE, Evans AM. What is the value of l ‐carnitine level determination for carnitine supplementation in hemodialysis patients? Hemodial Int 2013;17:335-8. [DOI: 10.1111/hdi.12021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
234 Foote MA. Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin. In: Elliott SG, Foote MA, Molineux G, editors. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Basel: Birkhäuser; 2009. pp. 77-85. [DOI: 10.1007/978-3-7643-8698-6_5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
235 Perrone RD, Coons SJ, Cavanaugh K, Finkelstein F, Meyer KB. Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. Am J Kidney Dis 2013;62:1046-57. [PMID: 23988757 DOI: 10.1053/j.ajkd.2013.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
236 Kesztyüs T, Simonsmeier U, Kesztyüs D. Developing a classification system for haemoglobin management in patients with end-stage renal disease on haemodialysis: a secondary data analysis. BMJ Open 2017;7:e017423. [PMID: 29122793 DOI: 10.1136/bmjopen-2017-017423] [Reference Citation Analysis]
237 Gabrilove JL. Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 2001;38:1-7. [PMID: 11523022 DOI: 10.1016/s0037-1963(01)90124-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. American Journal of Kidney Diseases 1996;28:910-7. [DOI: 10.1016/s0272-6386(96)90394-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
239 Deoreo PB, Eschbach JW. Implementation of the Anemia Guidelines. Advances in Renal Replacement Therapy 1999;6:18-27. [DOI: 10.1016/s1073-4449(99)70004-x] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
240 Movilli E, Carlo Cancarini G, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrology Dialysis Transplantation 2001;16:111-4. [DOI: 10.1093/ndt/16.1.111] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
241 Williams DE. Optimizing the effectiveness of hematopoietic growth factors. J Clin Immunol 1994;14:215-23. [DOI: 10.1007/bf01552307] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
242 Pannacciulli I, Castello G, Lerza R, Mencoboni M, Botta M, Arboscello E, Bogliolo G. Cisplatin inhibits erythroid committed progenitor (BFU-E) mobilization in peripheral blood. European Journal of Haematology 1998;61:65-70. [DOI: 10.1111/j.1600-0609.1998.tb01063.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Locatelli F, Baldamus CA, Villa G, Ganea A, Martín de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic-equivalence study. American Journal of Kidney Diseases 2002;40:119-25. [DOI: 10.1053/ajkd.2002.33920] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
244 Pan S, Chiang W, Chen Y. The journey from erythropoietin to 2019 Nobel Prize: Focus on hypoxia-inducible factors in the kidney. Journal of the Formosan Medical Association 2021;120:60-7. [DOI: 10.1016/j.jfma.2020.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney International 1997;51:622-30. [DOI: 10.1038/ki.1997.91] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 3.6] [Reference Citation Analysis]
246 Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF. Trends in Anemia Management among US Hemodialysis Patients. JASN 2002;13:1288-95. [DOI: 10.1097/01.asn.0000013294.11876.80] [Cited by in Crossref: 45] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
247 Van Buren PN, Inrig JK. Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. Pediatr Nephrol 2012;27:339-50. [PMID: 21286758 DOI: 10.1007/s00467-011-1775-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
248 Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol 2008;19:1389-95. [PMID: 18385423 DOI: 10.1681/ASN.2007111181] [Cited by in Crossref: 46] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
249 Besarab A, Frinak S, Yee J. An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy. JASN 1999;10:2029-43. [DOI: 10.1681/asn.v1092029] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
250 Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Pérez-Ruixo JJ. Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet 2013;52:1063-83. [PMID: 23912564 DOI: 10.1007/s40262-013-0098-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
251 Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol 2008;14:151-7. [PMID: 19568529 DOI: 10.4103/1319-3767.41739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
252 Hung SC, Kuo KL, Tarng DC, Hsu CC, Wu MS, Huang TP. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology (Carlton) 2014;19:735-9. [PMID: 25156587 DOI: 10.1111/nep.12332] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
253 Mccarthy JT, Hocum CL, Albright RC, Rogers J, Gallaher EJ, Steensma DP, Gudgell SF, Bergstralh EJ, Dillon JC, Hickson LJ, Williams AW, Dingli D. Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients. Mayo Clinic Proceedings 2014;89:87-94. [DOI: 10.1016/j.mayocp.2013.10.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
254 Dunea G, Swagel M, Bodiwala U, Arruda J. Intradialytic Oral Iron Therapy. Int J Artif Organs 1994;17:261-4. [DOI: 10.1177/039139889401700503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
255 Bamgbola OF, Kaskel F. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 2005;20:1622-9. [PMID: 16133045 DOI: 10.1007/s00467-005-2021-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
256 Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney International 2003;64:1514-21. [DOI: 10.1046/j.1523-1755.2003.00229.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 5.3] [Reference Citation Analysis]
257 Yan L, Colandrea VJ, Hale JJ. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat 2010;20:1219-45. [PMID: 20698812 DOI: 10.1517/13543776.2010.510836] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
258 Goodnough LT, Anderson KC. Recombinant growth factors. Transfus Sci 1995;16:45-62. [PMID: 10155704 DOI: 10.1016/0955-3886(94)00059-s] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
259 Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-8. [PMID: 10703677 DOI: 10.1681/ASN.V113530] [Cited by in Crossref: 71] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
260 Nissenson AR. Chronic peritoneal dialysis in the elderly. Geriatric Nephrol Urol 1991;1:3-12. [DOI: 10.1007/bf00451856] [Cited by in Crossref: 17] [Article Influence: 0.5] [Reference Citation Analysis]
261 Calvo JA, Miskulin DC, Meyer KB, Weiner DE. Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1621-7. [PMID: 20651155 DOI: 10.2215/CJN.02650310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
262 Shrum JP. Cytokines. Clinics in Dermatology 1996;14:331-6. [DOI: 10.1016/0738-081x(96)00062-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Yonemura Y, Kawakita M, Fujimoto K, Sakaguchi M, Takatsuki K, Kusuyama T, Hirose J, Kato K. Effects of short-term administration of recombinant human erythropoietin on rat megakaryopoiesis. The International Journal of Cell Cloning 1992;10:18-27. [DOI: 10.1002/stem.5530100105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
264 Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012;125:906-14.e9. [PMID: 22938926 DOI: 10.1016/j.amjmed.2012.03.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
265 Goldberg MA. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995;170:37S-43S. [PMID: 8546246 DOI: 10.1016/s0002-9610(99)80057-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
266 Zirkman DM, Zeigler ZR, Fraley DS, Bruns FJ, Adler S. Evaluation of Platelet Hyperfunction in Hemodialysis Patients Receiving Recombinant Human Erythropoietin. American Journal of Kidney Diseases 1993;21:31-7. [DOI: 10.1016/s0272-6386(12)80717-7] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
267 Chalhoub S, Langston CE, Farrelly J. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. J Vet Intern Med 2012;26:363-9. [PMID: 22296687 DOI: 10.1111/j.1939-1676.2011.00864.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
268 Teo GY, Rasedee A, Al-Haj NA, Beh CY, How CW, Rahman HS, Alitheen NB, Rosli R, Abdullah AH, Ali AS. Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells. Saudi J Biol Sci 2020;27:653-8. [PMID: 32210684 DOI: 10.1016/j.sjbs.2019.11.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
269 Cazzola M, Mercuriali F, Brugnara C. Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood 1997;89:4248-67. [DOI: 10.1182/blood.v89.12.4248] [Cited by in Crossref: 176] [Article Influence: 7.0] [Reference Citation Analysis]
270 Chevalier RL. New developments in pediatric nephrology. Current Problems in Pediatrics 1991;21:121-8. [DOI: 10.1016/0045-9380(91)90022-d] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
271 Lim SK, Goh BL, Visvanathan R, Kim SH, Jeon JS, Kim SG, Chang JH, Lim CS, Morad Z. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrol 2021;22:391. [PMID: 34823497 DOI: 10.1186/s12882-021-02601-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Salman M, Khan AH, Adnan AS, Sulaiman SA, Hussain K, Shehzadi N, Islam M, Jummaat F. Prevalence and management of anemia in pre-dialysis Malaysian patients: A hospital-based study. Rev Assoc Med Bras (1992) 2016;62:742-7. [PMID: 27992014 DOI: 10.1590/1806-9282.62.08.742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
273 Littlewood TJ. IS NORMALISING HAEMOGLOBIN IN PATIENTS WITH CKD HARMFUL AND IF SO, WHY? Journal of Renal Care 2009;35:25-8. [DOI: 10.1111/j.1755-6686.2009.00123.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
274 Eleftheriadis T, Antoniadi G, Liakopoulos V, Pissas G, Galaktidou G, Stefanidis I. Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients. Advances in Medical Sciences 2013;58:143-9. [DOI: 10.2478/v10039-012-0071-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
275 Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, Boccagno JA, Krantz SB. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161-8. [PMID: 2200263 DOI: 10.1016/0002-9343(90)90294-n] [Cited by in Crossref: 162] [Cited by in F6Publishing: 17] [Article Influence: 5.1] [Reference Citation Analysis]
276 Elia M. The application of nutritional science to clinical practice. Proc Nutr Soc 1994;53:1-14. [DOI: 10.1079/pns19940003] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
277 Veys N, Vanholder R, De Cuyper K, Ringoir S. Influence of Erythropoietin on Dialyzer Reuse, Heparin Need, and Urea Kinetics in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases 1994;23:52-9. [DOI: 10.1016/s0272-6386(12)80812-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
278 Gimenez LF, Scheel PJ. Clinical Application of Recombinant Erythropoietin in Renal Dialysis Patients. Hematology/Oncology Clinics of North America 1994;8:913-26. [DOI: 10.1016/s0889-8588(18)30137-0] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
279 Rachmilewitz EA, Aker M, Perry D, Dover G. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. British Journal of Haematology 1995;90:341-545. [DOI: 10.1111/j.1365-2141.1995.tb05156.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
280 Mccullough J. Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION: INNOVATION IN BLOOD BANKING. Transfusion 2010;50:2542-6. [DOI: 10.1111/j.1537-2995.2010.02787.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
281 Hung SC, Lin YP, Tarng DC. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc 2014;113:3-10. [PMID: 24090633 DOI: 10.1016/j.jfma.2013.09.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
282 Lundin AP. Recombinant Erythropoietin and Chronic Renal Failure. Hospital Practice 2016;26:61-9. [DOI: 10.1080/21548331.1991.11704158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
283 Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906. [PMID: 18845368 DOI: 10.1053/j.ajkd.2008.05.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 94] [Article Influence: 8.5] [Reference Citation Analysis]
284 Keven K, Kutlay S, Nergizoglu G, Ertürk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. American Journal of Kidney Diseases 2003;41:1233-9. [DOI: 10.1016/s0272-6386(03)00356-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
285 Parast L, Cheng SC, Cai T. Incorporating short-term outcome information to predict long-term survival with discrete markers. Biom J 2011;53:294-307. [PMID: 21337601 DOI: 10.1002/bimj.201000150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
286 Rasala BA, Muto M, Lee PA, Jager M, Cardoso RM, Behnke CA, Kirk P, Hokanson CA, Crea R, Mendez M, Mayfield SP. Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol J 2010;8:719-33. [PMID: 20230484 DOI: 10.1111/j.1467-7652.2010.00503.x] [Cited by in Crossref: 187] [Cited by in F6Publishing: 146] [Article Influence: 15.6] [Reference Citation Analysis]
287 Sui Z, Wang M, Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. Medicine (Baltimore) 2019;98:e13981. [PMID: 30633179 DOI: 10.1097/MD.0000000000013981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Trkulja V. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices. Med Hypotheses 2012;78:157-61. [PMID: 22078846 DOI: 10.1016/j.mehy.2011.10.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
289 Juul SE. Erythropoietin in the neonate. Curr Probl Pediatr 1999;29:129-49. [PMID: 10331138 DOI: 10.1016/s0045-9380(99)80055-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
290 Vansteenkiste J, Rossi G, Foote M. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. Expert Opinion on Biological Therapy 2005;3:501-8. [DOI: 10.1517/14712598.3.3.501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
291 Wright DG, Wright EC, Narva AS, Noguchi CT, Eggers PW. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015;10:1822-30. [PMID: 26358266 DOI: 10.2215/CJN.01590215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
292 Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol 2019;30:1037-48. [PMID: 31015255 DOI: 10.1681/ASN.2018101007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
293 Lim P, Yeh C, Hung T. Effects of recombinant human erythropoietin on echocardiographic findings in elderly dialysis patients. Nephrology 1997;3:149-54. [DOI: 10.1111/j.1440-1797.1997.tb00207.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Modrak M, Talukder MAH, Gurgenashvili K, Noble M, Elfar JC. Peripheral nerve injury and myelination: Potential therapeutic strategies. J Neurosci Res 2020;98:780-95. [PMID: 31608497 DOI: 10.1002/jnr.24538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
295 Pussell BA, Walker R. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Nephrology (Carlton) 2007;12:120-5. [PMID: 17371332 DOI: 10.1111/j.1440-1797.2006.00761.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
296 Spiegel DM, Khan I, Krishnan M, Mayne TJ. Changes in Hemoglobin Level Distribution in US Dialysis Patients From June 2006 to November 2008. American Journal of Kidney Diseases 2010;55:113-20. [DOI: 10.1053/j.ajkd.2009.09.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
297 Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-61. [PMID: 15064942 DOI: 10.1007/s00467-004-1457-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
298 Berns JS, Fishbane S, Elzein H, Lynn RI, Deoreo PB, Tharpe DL, Meisels IS. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodialysis International 2005;9:255-63. [DOI: 10.1111/j.1492-7535.2005.01139.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
299 Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecologic Oncology 1992;46:65-8. [DOI: 10.1016/0090-8258(92)90198-r] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
300 IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37:S182-S238. [PMID: 11229970 DOI: 10.1016/s0272-6386(01)70008-x] [Cited by in Crossref: 337] [Cited by in F6Publishing: 97] [Article Influence: 16.0] [Reference Citation Analysis]
301 Testa U. Erythropoietic stimulating agents. Expert Opinion on Emerging Drugs 2010;15:119-38. [DOI: 10.1517/14728210903499273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
302 King K. Vocational Rehabilitation in Maintenance Dialysis Patients. Advances in Renal Replacement Therapy 1994;1:228-39. [DOI: 10.1016/s1073-4449(12)80005-7] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
303 Humphries JE. Anemia of renal failure: Use of Erythropoietin. Medical Clinics of North America 1992;76:711-25. [DOI: 10.1016/s0025-7125(16)30349-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
304 Cardier JE, Foster DC, Lok S, Jacobsen SEW, Murphy MJ. Megakaryocytopoiesis In Vitro: From the Stem Cells&apos; Perspective. Stem Cells 1996;14:163-72. [DOI: 10.1002/stem.5530140721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
305 Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-798. [PMID: 18596733 DOI: 10.1038/ki.2008.295] [Cited by in Crossref: 347] [Cited by in F6Publishing: 291] [Article Influence: 24.8] [Reference Citation Analysis]
306 Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003;79:367-76. [PMID: 12897214 DOI: 10.1136/pmj.79.933.367] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
307 Korbet SM, Vonesh EF, Firanek CA. The Effect of Hematocrit on Peritoneal Transport. American Journal of Kidney Diseases 1991;18:573-8. [DOI: 10.1016/s0272-6386(12)80652-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
308 Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007;72:806-13. [PMID: 17597700 DOI: 10.1038/sj.ki.5002401] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
309 Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Semin Dial. 2006;19:279-284. [PMID: 16893404 DOI: 10.1111/j.1525-139x.2006.00173.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
310 Mallory D, Malamut D, Sandler SG. A Decade of Rare Donor Services in the United States. Vox Sanguinis 1992;63:186-91. [DOI: 10.1111/j.1423-0410.1992.tb05098.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
311 Prasad B, Jafari M, Toppings J, Gross L, Kappel J, Au F. Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients. Can J Kidney Health Dis 2020;7:2054358120927532. [PMID: 32547774 DOI: 10.1177/2054358120927532] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10. [PMID: 17699349 DOI: 10.2215/CJN.01110306] [Cited by in Crossref: 138] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
313 Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clinical Therapeutics 2003;25:1786-805. [DOI: 10.1016/s0149-2918(03)80170-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
314 Cho S, Lim H, Ghim J, Choe S, Kim U, Jung JA, Bae K. Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: An open-label, randomized-sequence, three-treatment, three-way crossover study. Clinical Therapeutics 2009;31:1046-53. [DOI: 10.1016/j.clinthera.2009.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
315 Kanda R, Kubo A, Seki T, Urita A, Sekiuchi M, Tomino Y. Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients. Ther Apher Dial 2021. [PMID: 34333847 DOI: 10.1111/1744-9987.13717] [Reference Citation Analysis]
316 Sawka MN, Convertino VA, Eichner ER, Schnieder SM, Young AJ. Blood volume: importance and adaptations to exercise training, environmental stresses, and trauma/sickness: . Medicine & Science in Sports & Exercise 2000;32:332. [DOI: 10.1097/00005768-200002000-00012] [Cited by in Crossref: 241] [Cited by in F6Publishing: 223] [Article Influence: 11.0] [Reference Citation Analysis]
317 Besarab A. Parenteral Iron Therapy: Safety and Efficacy. Seminars in Dialysis 2002;12:237-42. [DOI: 10.1046/j.1525-139x.1999.99028.x] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
318 Hon G, Vaziri N, Kaupke CJ, Tehranzadeh A, Barton C. Lack of a Fast-Acting Effect of Erythropoietin on Arterial Blood Pressure and Endothelin Level. Artificial Organs 1995;19:188-91. [DOI: 10.1111/j.1525-1594.1995.tb02309.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
319 Cotter DJ, Thamer M, Kimmel PL, Sadler JH. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996. Kidney International 1998;54:2129-39. [DOI: 10.1046/j.1523-1755.1998.00187.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
320 Muirhead N. Factors Affecting the Response to Erythropoietin in Chronic Renal Failure. Seminars in Dialysis 1991;4:5-8. [DOI: 10.1111/j.1525-139x.1991.tb00400.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
321 Jeong S, Cho YI, Duey M, Rosenson RS. Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment? Cardiovasc Drugs Ther 2010;24:151-60. [DOI: 10.1007/s10557-010-6239-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
322 Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney International 1991;39:155-63. [DOI: 10.1038/ki.1991.20] [Cited by in Crossref: 176] [Cited by in F6Publishing: 138] [Article Influence: 5.7] [Reference Citation Analysis]
323 Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 2009;54:498-510. [PMID: 19628315 DOI: 10.1053/j.ajkd.2009.05.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
324 Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009;4:e5894. [PMID: 19521513 DOI: 10.1371/journal.pone.0005894] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
325 Kaufman JS. Antithrombotic agents and the prevention of access thrombosis. Semin Dial 2000;13:40-6. [PMID: 10740671 DOI: 10.1046/j.1525-139x.2000.00012.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
326 Więcek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 2010;27:941-52. [PMID: 20972656 DOI: 10.1007/s12325-010-0080-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
327 Fares F, Ganem S, Hajouj T, Agai E. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. Endocrinology 2007;148:5081-7. [PMID: 17641000 DOI: 10.1210/en.2007-0026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
328 Powe NR, Griffiths RI, Greer JW, Watson AJ, Anderson GF, de Lissovoy G, Herbert RJ, Eggers PW, Milam RA, Whelton PK. Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney International 1993;43:1125-33. [DOI: 10.1038/ki.1993.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
329 Adamson JW. Cytokine biology. Implications for transfusion medicine. Cancer 1991;67:2708-11. [DOI: 10.1002/1097-0142(19910515)67:10+<2708::aid-cncr2820671707>3.0.co;2-a] [Cited by in Crossref: 7] [Article Influence: 0.2] [Reference Citation Analysis]
330 Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000;36:282-93. [PMID: 10922306 DOI: 10.1053/ajkd.2000.8972] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
331 Petersen J, Jani A. Delivery of erythropoietin with a needleless injection system during hemodialysis maintains plasma levels. ASAIO J 2001;47:608-10. [PMID: 11730196 DOI: 10.1097/00002480-200111000-00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
332 Singh AK. Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro. JASN 2009;20:1436-43. [DOI: 10.1681/asn.2009040444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
333 Imai E, Yamamoto R, Suzuki H, Watanabe T. Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol 2010;14:445-52. [DOI: 10.1007/s10157-010-0308-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
334 Jabs K, Harmon WE. Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther 1996;3:24-36. [PMID: 8620365 DOI: 10.1016/s1073-4449(96)80038-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
335 Standage BA, Schuman ES, Ackerman D, Gross GF, Ragsdale JW. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? The American Journal of Surgery 1993;165:650-4. [DOI: 10.1016/s0002-9610(05)80454-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
336 Stoian I, Manolescu B, Atanasiu V, Lupescu O. New alternatives for erythropoietin therapy in chronic renal failure. Open Medicine 2007;2:361-78. [DOI: 10.2478/s11536-007-0038-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
337 Walsh JR. Hematologic Problems. In: Cassel CK, Cohen HJ, Larson EB, Meier DE, Resnick NM, Rubenstein LZ, Sorensen LB, editors. Geriatric Medicine. New York: Springer; 1997. pp. 627-36. [DOI: 10.1007/978-1-4757-2705-0_41] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Hebert LA, Birmingham DJ, Shen X, Brandt JT, Sedmak DD, Dillon JJ. Effect of Recombinant Erythropoietin Therapy on Autoimmunity in Systemic Lupus Erythematosus. American Journal of Kidney Diseases 1994;24:25-32. [DOI: 10.1016/s0272-6386(12)80156-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
339 Deicher R, Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004;64:499-509. [PMID: 14977387 DOI: 10.2165/00003495-200464050-00004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
340 Foote M, Colowick A, Goodkin DA. Pharmacologic and cytokine treatment of commonly encountered anemias. Cytokines Cell Mol Ther 2002;7:49-59. [PMID: 12607795 DOI: 10.1080/13684730412331302090] [Reference Citation Analysis]
341 Pan SY, Chiang WC, Chen PM, Liu HH, Chou YH, Lai TS, Lai CF, Chiu YL, Lin WY, Chen YM, Chu TS, Lin SL. Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Sci Rep 2017;7:44013. [PMID: 28272424 DOI: 10.1038/srep44013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
342 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
343 Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. The Lancet 1993;341:1227-32. [DOI: 10.1016/0140-6736(93)91143-a] [Cited by in Crossref: 161] [Article Influence: 5.6] [Reference Citation Analysis]
344 Mikhail A, Shrivastava R, Richardson D. Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease. Nephron Clin Pract 2011;118:c101-24. [DOI: 10.1159/000328063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
345 Stivelman JC. Optimization of Iron Therapy in Hemodialysis Patients Treated with rHuEPO. Seminars in Dialysis 1994;7:288-92. [DOI: 10.1111/j.1525-139x.1994.tb00788.x] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
346 Jeffrey R, Khan A, Kendall R, Norfolk D, Will E, Davison A. Quantitative Reticulocyte Analysis May Be of Benefit in Monitoring Erythropoietin Treatment in Dialysis Patients. Artificial Organs 1995;19:821-6. [DOI: 10.1111/j.1525-1594.1995.tb02434.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
347 Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 2009;83:122-30. [PMID: 19122476 DOI: 10.1159/000189027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
348 Elia M. Changing concepts of nutrient requirements in disease: implications for artificial nutritional support. Lancet 1995;345:1279-84. [PMID: 7746061 DOI: 10.1016/s0140-6736(95)90929-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
349 Sheffield RE, Sullivan SD, Saltiel E, Nishimura L. Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia. Ann Pharmacother 1997;31:15-22. [DOI: 10.1177/106002809703100101] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
350 Birkhoff WAJ, Heuberger JAAC, Post TE, Gal P, Stuurman FE, Burggraaf J, Cohen AF. Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists. Physiol Rep 2018;6:e13924. [PMID: 30592183 DOI: 10.14814/phy2.13924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
351 Eleftheriadis T, Pissas G, Remoundou M, Filippidis G, Antoniadi G, Oustampasidou N, Liakopoulos V, Stefanidis I. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin. Int Urol Nephrol 2014;46:161-7. [PMID: 23860963 DOI: 10.1007/s11255-013-0497-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
352 Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014;89:88-96. [PMID: 24122955 DOI: 10.1002/ajh.23598] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 16.4] [Reference Citation Analysis]
353 Apostolou T, Gokal R. Quality of life after peritoneal dialysis. In: Gokal R, Khanna R, Krediet RT, Nolph KD, editors. Textbook of Peritoneal Dialysis. Dordrecht: Springer Netherlands; 2000. pp. 709-35. [DOI: 10.1007/978-94-017-3225-3_23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
354 Dessypris EN, Krantz SB. Erythropoietin: Regulation of Erythropoiesis and Clinical Use. Elsevier; 1990. pp. 127-47. [DOI: 10.1016/s1054-3589(08)60341-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
355 Yeun JY, Ornt DB, Depner TA. Hemodialysis. Brenner and Rector's The Kidney. Elsevier; 2012. pp. 2294-346. [DOI: 10.1016/b978-1-4160-6193-9.10064-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
356 Lebel M, Grose JH, Kingma I, Langlois S. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 1994;16:565-75. [PMID: 7951163 DOI: 10.3109/10641969409067962] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
357 Kaufman JM, Hatzichristou DG, Mulhall JP, Fitch WP, Goldstein I. Impotence and Chronic Renal Failure: A Study of the Hemodynamic Pathophysiology. Journal of Urology 1994;151:612-8. [DOI: 10.1016/s0022-5347(17)35030-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
358 Morris KP, Watson S, Reid MM, Hamilton PJ, Coulthard MG. Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use? Pediatr Nephrol 1994;8:51-6. [PMID: 8142226 DOI: 10.1007/BF00868261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med 2014;174:699-707. [PMID: 24589911 DOI: 10.1001/jamainternmed.2014.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
360 Jabs K, Harmon WE. Anemia and Its Treatment in Children on CAPD/CCPD. In: Fine RN, Alexander SR, Warady BA, editors. CAPD/CCPD in Children. Boston: Springer US; 1998. pp. 183-97. [DOI: 10.1007/978-1-4615-4931-4_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
361 Schuster SJ, Caro J. Erythropoietin: Physiologic Basis for Clinical Applications. Vox Sanguinis 1993;65:169-79. [DOI: 10.1111/j.1423-0410.1993.tb02143.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
362 Pascual J, Teruel J, Marcén R, Ortuño F, Liaño J. Blood Pressure after three Different forms of Correction of Anemia in Hemodialysis. Int J Artif Organs 1992;15:393-6. [DOI: 10.1177/039139889201500703] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
363 Lacson E, Brunelli SM. Hemodialysis Treatment Time: A Fresh Perspective. CJASN 2011;6:2522-30. [DOI: 10.2215/cjn.00970211] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
364 Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32:1373-1386. [PMID: 28371815 DOI: 10.1093/ndt/gfx011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 23.3] [Reference Citation Analysis]
365 Zachée P. Controversies in selection of epoetin dosages. Issues and answers. Drugs 1995;49:536-47. [PMID: 7789287 DOI: 10.2165/00003495-199549040-00004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
366 Levin A, Beaulieu MC. TREAT: Implications for Guideline Updates and Clinical Care. American Journal of Kidney Diseases 2010;55:984-7. [DOI: 10.1053/j.ajkd.2010.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
367 Kaupke C, Vaziri N. Effect of Recombinant Erythropoietin on Electrolytes and Nutrition in End-Stage Renal Disease Patients. Int J Artif Organs 1993;16:59-62. [DOI: 10.1177/039139889301600201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
368 Hanna JD, Foreman JW, Chan JC. Chronic renal insufficiency in infants and children. Clin Pediatr (Phila) 1991;30:365-84. [PMID: 1860277 DOI: 10.1177/000992289103000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
369 Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-75. [PMID: 20609178 DOI: 10.1111/j.1744-9987.2010.00836.x] [Cited by in Crossref: 156] [Cited by in F6Publishing: 127] [Article Influence: 13.0] [Reference Citation Analysis]
370 Casserly LF, Reddy SM, Dember LM. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 2000;36:405-11. [PMID: 10922321 DOI: 10.1053/ajkd.2000.8983] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
371 Golab J, Zagozdzon R, Stoklosa T, Lasek W, Jakobisiak M, Pojda Z, Machaj E. Erythropoietin Prevents the Development of Interleukin-12–Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. Blood 1998;91:4387-8. [DOI: 10.1182/blood.v91.11.4387] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
372 Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA. Trends in Anemia Management in Hemodialysis Patients with Cancer. Am J Nephrol 2015;42:206-15. [PMID: 26439712 DOI: 10.1159/000440771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
373 Rizzuto G, Cappelletti M, Mennuni C, Wiznerowicz M, Demartis A, Maione D, Ciliberto G, Monica NL, Fattori E. Gene Electrotransfer Results in a High-Level Transduction of Rat Skeletal Muscle and Corrects Anemia of Renal Failure. Human Gene Therapy 2000;11:1891-900. [DOI: 10.1089/10430340050129503] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
374 Zhang L, Gong AG, Riaz K, Deng JY, Ho CM, Lin HQ, Dong TT, Lee YK, Tsim KW. A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats. FEBS Open Bio 2017;7:318-23. [PMID: 28286727 DOI: 10.1002/2211-5463.12146] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
375 Lindenfeld J, Keebler ME. Left ventricular assist device thrombosis: another piece of the puzzle? JACC Heart Fail 2015;3:154-8. [PMID: 25660840 DOI: 10.1016/j.jchf.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
376 Zauli G, Gibellini D, Vitale M, Secchiero P, Celeghini C, Bassini A, Pierpaoli S, Marchisio M, Guidotti L, Capitani S. The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. Blood 1998;92:472-80. [DOI: 10.1182/blood.v92.2.472] [Cited by in Crossref: 25] [Article Influence: 1.0] [Reference Citation Analysis]
377 Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H; TREAT Investigators. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009;54:59-69. [PMID: 19501439 DOI: 10.1053/j.ajkd.2009.04.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
378 Stewart WK. Erythropoietin — Trials Then Tribulation. Scott Med J 1991;36:3-4. [DOI: 10.1177/003693309103600101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
379 Watson A. Iron Management During Treatment with Recombinant Human Erythropoietin in Chronic Renal Failure. The Journal of Clinical Pharmacology 1993;33:1134-8. [DOI: 10.1002/j.1552-4604.1993.tb03912.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
380 Eschbach JW, Adamson JW. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney International 1999;55:S35-43. [DOI: 10.1046/j.1523-1755.1999.055suppl.69035.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
381 Jones MA, Kingswood JC, Dallyn PE, Sharpstone P. Haemodynamic Changes Measured by Transthoracic Bioimpedance During Treatment with Recombinant Human Erythropoietin. Clinical and Experimental Hypertension 2009;18:51-64. [DOI: 10.3109/10641969609082606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
382 Littlewood T. Normalization of Hemoglobin in Patients With CKD May Cause Harm: But What Is the Mechanism? American Journal of Kidney Diseases 2008;52:642-4. [DOI: 10.1053/j.ajkd.2008.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
383 Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol 2013;69:929-36. [DOI: 10.1007/s00228-012-1412-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
384 Wish JB, Coyne DW. Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies. Mayo Clinic Proceedings 2007;82:1371-80. [DOI: 10.4065/82.11.1371] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
385 Campos A, Garin EH. Therapy of Renal Anemia in Children and Adolescents with Recombinant Human Erythropoietin (rHuEPO). Clin Pediatr (Phila) 1992;31:94-9. [DOI: 10.1177/000992289203100206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
386 Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol 2019;15:731-2. [DOI: 10.1038/s41581-019-0207-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
387 Hynes DM, Stroupe KT, Greer JW, Reda DJ, Frankenfield DL, Kaufman JS, Henderson WG, Owen WF, Rocco MV, Wish JB, Kang J, Feussner JR. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002;112:169-75. [PMID: 11893342 DOI: 10.1016/s0002-9343(01)01103-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
388 Choukroun G, Renou M, Lecaque C, Jauréguy M. [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4]. Nephrol Ther 2011;7:2-9. [PMID: 21216683 DOI: 10.1016/j.nephro.2010.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
389 Fishbane S, Nissenson AR. Anemia management in chronic kidney disease. Kidney International 2010;78:S3-9. [DOI: 10.1038/ki.2010.188] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
390 Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 2009;9:10. [PMID: 19463151 DOI: 10.1186/1472-6904-9-10] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
391 Eschbach JW. Anemia Management in Chronic Kidney Disease: Role of Factors Affecting Epoetin Responsiveness. JASN 2002;13:1412-4. [DOI: 10.1097/01.asn.0000016440.52271.f7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
392 Reuter SE, Faull RJ, Ranieri E, Evans AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant. 2009;24:990-996. [PMID: 18987259 DOI: 10.1093/ndt/gfn588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
393 Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis 2009;16:131-42. [PMID: 19233072 DOI: 10.1053/j.ackd.2008.12.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
394 Liu J, Li S, Gilbertson DT, Monda KL, Bradbury BD, Collins AJ. Development of a Standardized Transfusion Ratio as a Metric for Evaluating Dialysis Facility Anemia Management Practices. American Journal of Kidney Diseases 2014;64:608-15. [DOI: 10.1053/j.ajkd.2014.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
395 Song KE, Byeon J, Moon DB, Kim HH, Choi YJ, Suh JK. Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis. Mol Cells 2014;37:819-26. [PMID: 25284312 DOI: 10.14348/molcells.2014.0214] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
396 Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-1343. [PMID: 16105069 DOI: 10.1111/j.1523-1755.2005.00532.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 150] [Article Influence: 12.8] [Reference Citation Analysis]
397 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
398 Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney International 2009;75:358-65. [DOI: 10.1038/ki.2008.467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
399 Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res 2014;6:319-30. [PMID: 25050070 DOI: 10.2147/CEOR.S46930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
400 Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-60. [PMID: 15331889 DOI: 10.1159/000080452] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
401 Paganini EP, Eschbach JW, Lazarus J, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA. Intravenous versus subcutaneous dosing of Epoetin alfa in hemodialysis patients. American Journal of Kidney Diseases 1995;26:331-40. [DOI: 10.1016/0272-6386(95)90654-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
402 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
403 Sayinalp N, Erdem Y, Özcebe Oİ, Büyükaşik Y, Çağlar Ş, Dündar SV. Recombinant Human Erythropoietin Increases Platelet Aggregation in Chronic Hemodialysis Patients. Thrombosis Research 1998;90:195-8. [DOI: 10.1016/s0049-3848(98)00066-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial. The Journal of Pediatrics 1996;129:656-60. [DOI: 10.1016/s0022-3476(96)70145-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
405 Macdougall IC, Wiecek A, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Smolenski O, Sułowicz W, Mayo M, Francisco C, Polu KR, Schatz PJ, Duliege AM. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011;6:2579-86. [PMID: 21940838 DOI: 10.2215/CJN.10831210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
406 Zotter H, Robinson N, Zorzoli M, Schattenberg L, Saugy M, Mangin P. Abnormally high serum ferritin levels among professional road cyclists. Br J Sports Med 2004;38:704-8. [PMID: 15562163 DOI: 10.1136/bjsm.2003.006635] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
407 Spivak JL. Serum immunoreactive erythropoietin in health and disease. J Perinat Med 1995;23:13-7. [PMID: 7658313 DOI: 10.1515/jpme.1995.23.1-2.13] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
408 Skali H, Lin J, Pfeffer MA, Chen C, Cooper ME, Mcmurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm. American Journal of Kidney Diseases 2013;61:238-46. [DOI: 10.1053/j.ajkd.2012.08.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
409 Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011;22:358-65. [PMID: 21164028 DOI: 10.1681/ASN.2010020173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
410 Kang ES, Acchiardo SR, Kang AH. Implications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension. Free Radical Research 2009;35:341-65. [DOI: 10.1080/10715760100300871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
411 Warady BA, Alexander S, Schaefer F. Peritoneal Dialysis in Children. In: Khanna R, Krediet RT, editors. Nolph and Gokal’s Textbook of Peritoneal Dialysis. Boston: Springer US; 2009. pp. 803-59. [DOI: 10.1007/978-0-387-78940-8_29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
412 Chernova I, Krishnan N. Resistant Hypertension Updated Guidelines. Curr Cardiol Rep 2019;21:117. [PMID: 31471727 DOI: 10.1007/s11886-019-1209-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
413 Cotter DJ, Stefanik K, Zhang Y, Thamer M. Improved survival with higher hematocrits: where is the evidence? Semin Dial 2004;17:181-3. [PMID: 15144538 DOI: 10.1111/j.0894-0959.2004.17317.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
414 Mccullough J. Transfusion medicine: discipline with a future. Transfusion 2003;43:823-8. [DOI: 10.1046/j.1537-2995.2003.00417.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
415 Cohen RA, Brown RS. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk? Am J Kidney Dis 2012;59:604-6. [PMID: 22361042 DOI: 10.1053/j.ajkd.2011.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
416 Picon PD, Pribbernow SC, Prompt CA, Schacher SC, Antunes VV, Mentz BP, Oliveira FL, Souza CM, Schacher FC. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. Clinics (Sao Paulo) 2014;69:547-53. [PMID: 25141114 DOI: 10.6061/clinics/2014(08)08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
417 Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. Journal of Clinical Epidemiology 2004;57:1086-95. [DOI: 10.1016/j.jclinepi.2004.05.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
418 Carson JL, Willett LR. Is a hemoglobin of 10 g/dL required for surgery? Medical Clinics of North America 1993;77:335-47. [DOI: 10.1016/s0025-7125(16)30255-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
419 Sasaki N, Ando Y, Kusano E, Asano Y. A case of erythropoietin induced hypertension in a bilaterally nephrectomized patient. ASAIO J 2003;49:131-5. [PMID: 12558321 DOI: 10.1097/00002480-200301000-00022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995;26:S1-24. [PMID: 7645549 DOI: 10.1016/0272-6386(95)90645-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
421 Means RT. Clinical Application of Recombinant Erythropoietin in the Anemia of Chronic Disease. Hematology/Oncology Clinics of North America 1994;8:933-44. [DOI: 10.1016/s0889-8588(18)30139-4] [Cited by in Crossref: 13] [Article Influence: 0.5] [Reference Citation Analysis]
422 Jurado García JM, Torres Sánchez E, Olmos Hidalgo D, Alba Conejo E. Erythropoietin pharmacology. Clin Transl Oncol 2007;9:715-22. [PMID: 18055326 DOI: 10.1007/s12094-007-0128-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
423 Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 1994;53:265-70. [PMID: 7813706 DOI: 10.1111/j.1600-0609.1994.tb01318.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
424 Klingemann H, Shepherd JD, Eaves CJ, Eaves AC. The Role of Erythropoietin and Other Growth Factors in Transfusion Medicine. Transfusion Medicine Reviews 1991;5:33-47. [DOI: 10.1016/s0887-7963(91)70191-0] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
425 Bauer C. Erythropoietin — from gene structure to therapeutic applications. Journal of Perinatal Medicine 1995;23:77-82. [DOI: 10.1515/jpme.1995.23.1-2.77] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
426 Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney International 1992;42:407-16. [DOI: 10.1038/ki.1992.302] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 1.8] [Reference Citation Analysis]
427 Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1-14. [PMID: 12524467 DOI: 10.1177/153537020322800101] [Cited by in Crossref: 493] [Cited by in F6Publishing: 429] [Article Influence: 25.9] [Reference Citation Analysis]
428 Brown KR, Carter W Jr, Lombardi GE. Recombinant erythropoietin overdose. Am J Emerg Med 1993;11:619-21. [PMID: 8240567 DOI: 10.1016/0735-6757(93)90017-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]